UCLA Broad Stem Cell

At UCLA, Dr. David Nathanson is designing new therapies that tackle glioblastoma’s unique tumor biology, aiming to overcome long-standing treatment challenges. newsroom.ucla.edu/stories/the-sc…

By day, Dr. Anthony Aldave advances gene therapy for inherited corneal disorders. After hours, he’s spinning EDM. Learn about the @UCLASteinEye surgeon-scientist’s path to ophthalmology, global training work and mission to restore sight: ow.ly/PTua50YVHig

Congratulations to Dr. Aparna Bhaduri @BhaduriLab for receiving the 2026 Pershing Square Sohn Cancer Prize, a national award recognizing innovative early-career scientists pursuing bold approaches to cancer research! 🎉 🔗 bit.ly/4tkEE0Q #ResearchPowersProgress

Meet Dr. Anthony Aldave, a corneal surgeon @UCLASteinEye & #GeneTherapy pioneer working to restore sight for people with inherited corneal disorders. Learn about his path to ophthalmology, global surgical training work and after-hours life as a DJ: ow.ly/PTua50YVHig

Don't miss Xiaowei Zhuang, Ph.D. of @Harvard University present, "Spatially Resolved Single-Cell Genomics & Functional Genomics," on Friday, May 8 at 12PM PT via Zoom: ow.ly/UllR50YVa4b @UCLAHealth

Aging biology is moving fast. New work from @dgsomucla from @ACovarrubiasPhD highlights how “zombie” immune cells (senescent macrophages) in the liver build up with age and drive chronic inflammation. A powerful example of how training, discovery & collaboration are advancing our understanding of aging—and pointing toward new therapies. nature.com/articles/s4358…

Hair loss treatments haven’t meaningfully changed in decades. Pelage was built to change that. We're advancing PP405, a topical therapy designed to reactivate dormant hair follicle stem cells to restore hair growth, with plans to initiate late-stage trials later this year. Read our full story below. latimes.com/b2b/health-lif…

For the first time, UCLA scientists @LTULab have mapped how Down syndrome reshapes the human brain before birth — uncovering surprising shifts in neuron development that may explain differences in brain size and cognition. Read more ➡️bit.ly/4ebcP7z #BrainDevelopment

A clinical trial for sickle cell disease that UCLA's @Kohn_Lab led over nearly a decade yields hard-won insights — and a roadmap for better clinical trial design for blood diseases. Read more ➡️ bit.ly/4vHEX8y #ResearchPowersProgress #SickleCellDisease #GeneTherapy

In collaboration with Dr. Jasmine Zhou and an incredible team of UCLA scientists, our director has published in the Proceedings of the National Academy of Sciences a new low-cost blood test to detect and monitor many diseases including ovarian cancer. uclahealth.org/news/release/u…

About 1 in 3 Angelenos has fatty liver disease. @UCLA scientists may have just found a new way to treat it by targeting dysfunctional immune cells dubbed "zombie cells." 🧟🧫 #ResearchPowersProgress @ACovarrubiasPhD stemcell.ucla.edu/news/ucla-scie…

Online now!✨RESEARCH: Salladay-Perez and colleagues interrogate whether macrophages can really undergo senescence, and characterize a p21+Trem2+ senescent macrophage population functionally implicated in inflammaging and liver disease @ACovarrubiasPhD nature.com/articles/s4358…

ICYMI: FDA approval of a new gene therapy marks a major advance in treating a rare and life-threatening immune disorder in children. newsroom.ucla.edu/in-the-news/fd…

The FDA has approved a gene therapy developed at UCLA for a rare immune disorder, with clinical trial patients showing restored immune function. newsroom.ucla.edu/releases/fda-a…

Read more: bit.ly/4sUCztg #StemCells #RareDisease

All 3 Langenhop kids were born with a rare, often-fatal immune disorder called LAD-I. After joining a UCLA #GeneTherapy trial, they're now "normal, happy kids" with functional immune systems. Their trial participation helped make last week’s FDA accelerated approval possible. 💙

In collaboration with @RocketPharma , we celebrate the first FDA-approved gene therapy supported by @CIRMnews and CA taxpayer funding. #raredisease matters.

The FDA approved a gene therapy for severe leukocyte adhesion deficiency type 1 (LAD-1), an ultra-rare disease that leaves children vulnerable to life-threatening infections. trib.al/ZW299KK

How does the FDA-approved LAD-I gene therapy work? Doctors take the patient's OWN stem cells, add a healthy copy of the mutated gene, and return them. No donor needed. No transplant rejection risk. All 9 trial patients: restored immune systems. 🔗 lnkd.in/gDJzjgvx

The FDA has granted accelerated approval for KRESLADI, a gene therapy for LAD-I — a rare immune disorder that can be fatal in young children. Led by @Kohn_Lab @UCLA, all 9 clinical trial patients survived with restored immune function. 🔗bit.ly/4uVBcfg #GeneTherapy